Muscle quality on MRI may foretell liver transplant success

NCT ID NCT05477277

Recruiting now Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This study explores whether a new MRI-based muscle assessment score (MAsS) can predict adverse outcomes in people with end-stage liver disease who are candidates for a liver transplant. Researchers will measure muscle fat and volume from standard MRI scans and track hospital stays, ICU days, and survival after transplant. The goal is to see if muscle composition offers a simple way to identify higher-risk patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MRI-based Muscle Assessment Score (MAsS) added to standard MRI scans
What this could lead to: If successful, this could help doctors better predict which liver transplant candidates face higher risks, potentially improving care and outcomes.
What could go wrong: This is a small pilot study, so findings may not be definitive. The muscle score's predictive value is unproven and may not change clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic liver failure cirrhosis of liver End Stage Liver Disease Fibrosis Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CIRRHOSIS END STAGE LIVER DISEASE SARCOPENIA SARCOPENIC OBESITY

Contacts and locations

Locations

Mayo Clinic Arizona
RECRUITING

Phoenix, Arizona, 85259, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.